Axsome Therapeutics (AXSM) Accumulated Expenses (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Accumulated Expenses data on file, last reported at $27.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 37.89% year-over-year to $27.0 million; the trailing twelve-month figure through Mar 2026 stood at $27.0 million (up 37.89% YoY), and the FY2025 full-year result was $150.2 million, up 1.53% from the prior year.
• Accumulated Expenses slipped to $27.0 million in Q1 2026, from $150.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $150.2 million in Q4 2025 to a low of $1.3 million in Q1 2023.
• A 5-year average of $28.1 million and a median of $13.6 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses sank 49.29% in 2022 and soared 2175.67% in 2024, its largest moves.
• Tracing AXSM's Accumulated Expenses over 5 years: stood at $4.7 million in 2022, then surged by 37.95% to $6.5 million in 2023, then soared by 2175.67% to $148.0 million in 2024, then gained by 1.53% to $150.2 million in 2025, then sank by 82.01% to $27.0 million in 2026.
• Business Quant data shows AXSM's Accumulated Expenses at $27.0 million in Q1 2026, $150.2 million in Q4 2025, and $12.7 million in Q3 2025.